Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ)
The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor), containing CD8 hinge, 4-1BB and CD3ζ signaling domains. The lentiviruses also contain a puromycin selection marker (Figure 1).
A.
B. 
Figure 1. (A) Schematic of the lenti-vector used to generate the anti-CD19 CAR lentivirus. This vector contains a puromycin selection. (B) Construct diagram showing components of the anti-CD19 CAR.
Note: This product transduces the same anti-CD19 CAR construct (CD19 ScFv-CD8-4-1BB-CD3ζ) as other available anti-CD19 CAR Lentiviruses (BPS Bioscience # 78601, 78602 and 78775), but differ in key aspects. This product contains a puromycin selection marker that can be used for selection. Please see table below.
| BPS Bioscience # | Self-Inactivation (SIN) | Selection Marker |
| 78600 | no | puromycin |
| 78601 | yes | no |
| 78602 | yes | puromycin |
| 78775 | yes | eGFP |
| Name | Ordering Information |
| PBMC, Frozen | BPS Bioscience #79059 |
| Human Interleukin-2 | BPS Bioscience #90184 |
| EasySep™ Human CD4+ T Cell Isolation Kit | Stemcell technologies, #17952 |
| EasySep™ Human CD8+ T Cell Isolation Kit | Stemcell technologies, #17953 |
| Human CD3/CD28/CD2 T Cell Activator | Stemcell technologies, #10970 |
| PE-Labeled Anti-FMC63 scFv Monoclonal | Acrobiosystems # FM3-HPY53-25tests |
| IFN-γ (Human) Colorimetric ELISA Detection Kit | BPS Bioscience #79777 |
| CD19 / Firefly Luciferase - CHO Recombinant Cell Line | BPS Bioscience #79714 |
| Firefly Luciferase - CHO Recombinant Cell Line | BPS Bioscience #79725 |
| ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
The lentiviruses were produced from HEK293T cells, concentrated, and resuspended in DMEM. Virus particles can be packaged in custom formulations by special request, for an additional fee.
CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.